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Fibroblast growth factor receptor signalling is dictated by
specific heparan sulphate saccharides
Scott E. Guimond and Jeremy E. Turnbull
Signalling by fibroblast growth factors (FGFs) through
FGF receptors (FGFRs) depends on the cell-surface
polysaccharide heparan sulphate (HS) [1,2]. HS has an
ordered domain structure of highly diverse saccharide
motifs that present unique displays of sulphate,
carboxyl and hydroxyl groups [3]. These motifs interact
with many proteins, particularly growth factors. HS
binds both to FGFs [4–6] and FGFRs [7], and probably
activates signalling by facilitating ligand-induced
receptor dimerisation [8,9]. Nevertheless, the extent to
which specific HS saccharide sequences play a
regulatory role has not been established. By screening
a library of structurally diverse HS decasaccharides in
bioassays of FGF signalling mediated by three different
FGFR isoforms, we found that saccharides showed
specificity for both ligands and receptors; some
saccharides selectively activated FGF signalling
through different FGFR isoforms, others acted as
negative regulators. We conclude that HS saccharides
play critical roles in dictating the specificity of
ligand–receptor interactions in FGFR signalling.
Controlled alterations in HS structures [10] would
provide a mechanism for regulation of cellular
responsiveness to growth factors that bind HS.
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Results and discussion
Recent studies have shown important functional roles for
HS that depend on specific structural modifications (see
Supplementary material for additional background). Saccha-
rides from the sulphated domains of HS can differentially
activate FGF-2 signalling [11,12], and cell-type-specific
HS chains can regulate ligand–receptor binding [7,13].
These studies raise the intriguing possibility that distinct
HS saccharide sequences regulate FGF–FGFR interac-
tions. To determine the regulatory role of saccharide
specificity in FGF signalling, we first prepared a set of
size-defined HS saccharides from porcine mucosal HS, a
tissue source of HS chains rich in highly complex mixtures
of N- and O-sulphated saccharide species [11,12]. Follow-
ing treatment with the enzyme heparitinase, the saccha-
ride products were fractionated by size exclusion
chromatography to produce size-defined mixtures from
dp4 to dp20 (4–20 monosaccharide units). Using strong
anion-exchange high-performance liquid chromatography
(SAX-HPLC), we then purified a library of 27 structurally
diverse decasaccharide fractions for initial activity screen-
ing (Figure 1), decasaccharides being the minimal size for
FGF-2 activation [12]. Some were single peaks and others
were tightly clustered groups of 2–4 peaks that probably
represent isomers with slight structural variations (see
Supplementary material).
We initially investigated signalling by a single ligand,
FGF-2, mediated by the immunoglobulin-like loop IIIc
splice variant of the FGFR isoform 1 (FGFR1c) expressed
in HS-deficient BaF3 cells, a well-characterised model for
systematic comparisons of the responses of FGFR iso-
forms. In these cells, responses to FGF are dependent on
the addition of exogenous activating saccharides or heparin
([14]; see also Supplementary material). Activity screening
of all the saccharide fractions showed that they had differ-
ing abilities to activate signalling by FGFR1c in response
to FGF-2 (Figure 2a). Whereas some were as active as
Figure 1
Preparation of a HS decasaccharide library by high resolution SAX-
HPLC. HS decasaccharides were prepared from porcine mucosal HS
and subjected to SAX-HPLC as described previously ([16]; see also
Supplementary material). The figure shows a typical preparative run.
Multiple separations of 1 mg per run were performed and identical
peak fractions (labelled A–Z) pooled, desalted and weighed before
bioassay analysis.
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heparin, others elicited only intermediate levels of activa-
tion or were incapable of supporting FGF-2 signalling. We
then determined whether saccharides differed in their
ability to activate signalling by FGF-2 mediated by the
FGFR isoforms 2 and 3 (FGFR2c and FGFR3c, respec-
tively) expressed in HS-deficient BaF3 cells. Surprisingly,
we observed striking differences in the activity profiles of
the decasaccharides (Figure 2). Some saccharides activated
FGFR1c but not FGFR2c (for example, fractions G, H
and I) and vice versa (for example, fractions B and D;
Figure 2a,b). In contrast, only a few of the decasaccharide
fractions (for example, A and C) activated FGFR3c, and
only weakly (Figure 2c). We subsequently tested the size-
defined HS saccharide mixtures and observed that only
very large saccharides (dp ≥ 18) were able to strongly acti-
vate FGF-2 signalling mediated by FGFR3c, although
weak responses were elicited by fractions in the size range
dp12–16 (see Supplementary material). This activity
profile is distinct from that for FGF-2 signalling through
FGFR1c in which only fractions of size dp12 and larger
were able to strongly activate signalling, and the decasac-
charide fraction displayed weak activity (~10% of heparin
control). This size-dependent difference in FGFR3c acti-
vation might reflect an absolute requirement for longer sac-
charide sequences, or alternatively that smaller specific
activating sequences are harboured only within the larger
saccharide fractions. 
It was also surprising that, for FGFR2c signalling, some of
the saccharides (for example, fractions B–E) were consider-
ably more potent than heparin (Figure 2b), and this behav-
iour was maintained over a wide range of concentrations
(for example, fraction D; see Supplementary material). In
contrast, the most potent activators of FGFR1c were
similar in maximum activity to heparin (Figure 2a),
although they were typically less potent at lower doses (for
example, fraction V; see Supplementary material). To our
knowledge, this is the first demonstration of significantly
greater activity of HS saccharides than heparin in FGF sig-
nalling, and suggests that FGFR2c is not maximally acti-
vated by heparin sequences. It should, however, be noted
that this comparison is on the basis of weight-equivalent
rather than equimolar amounts of saccharides. Their differ-
ing lengths and molecular weights (approximately 3 kDa
for decasaccharides and 12 kDa for heparin) could con-
tribute to differences in activity and further comparisons
with purified heparin decasaccharides will be required to
address this point. Heparin is found only in mast cells
unlike HS, which is very widely expressed in metazoan
organisms and is the predominant physiologically relevant
molecule. Our data indicate that use of heparin as a surro-
gate experimental molecule for HS has precluded recogni-
tion of the functional specificity of cellular HS sequences.
Moreover, our results also show that previous experiments
on the ligand specificity of FGFRs in the presence of
heparin [14] do not fully reflect the role that HS saccha-
rides might play in dictating ligand specificity. 
As previous studies indicated that some HS saccharides
can inhibit FGF-2 activation [12], we also tested the
ability of the decasaccharides to act as negative regulators
of FGF-2 signalling. We observed that some saccharides
that did not activate FGF-2 signalling through a particular
receptor showed no significant activity (for example, frac-
tion R for FGFR1c and FGFR2c), but others (for example,
fractions T and X′ for FGFR1c, and V and X′ for FGFR2c)
selectively inhibited FGF-2 signalling in the presence of a
sub-maximally activating dose of heparin (see Supplemen-
tary material). It is notable that these negative regulators
were active at concentrations similar to those at which pos-
itive regulators were active (30–1000 ng/ml). Moreover,
some saccharides that inhibited one FGFR activated a dif-
ferent isoform. For example, fraction V inhibited FGFR2c
(see Supplementary material) but was a potent activator of
FGFR1c (Figure 2a); and fraction T inhibited FGFR1c at
high concentrations but activated FGFR2c (Figure 2b). 
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Figure 2
FGF-2 signalling by FGFR isoforms is
differentially regulated by specific HS
saccharides. Activation of FGF signalling was
measured in bioassays of mitogenesis using
BaF3 cells as described previously ([14]; for
details, see Supplementary material). BaF3
cells expressing (a) FGFR1c, (b) FGFR2c, or
(c) FGFR3c were treated with 1 nM
(18 ng/ml) FGF-2 in the presence of the
decasaccharide fractions shown (designated
A–Z; see Figure 1) or a positive control of
heparin (both at 1 µg/ml). A colorimetric assay
was used to assess the proliferative
responses. Assays were performed in
triplicate and expressed as a percentage
(mean ± SD) of the heparin control (level
indicated by dashed line).
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In contrast to the unexpected FGFR-specific mode of
action of the saccharides, differential effects of specific HS
saccharides on signalling by FGFs is expected because of
the different structural requirements for binding of HS to
various FGFs [4–6]. To examine this possibility, we tested
the ability of the decasaccharide fractions to act as regula-
tors of FGF-1 signalling. In contrast to FGF-2, none of
these saccharides activated FGF-1 signalling mediated by
FGFR1c in BaF3 cells (data not shown). This indicates a
different HS sequence requirement for activation of
FGF-1, but an additional factor could be the length of the
saccharides. We tested this possibility using the size-
defined HS saccharide mixtures. There was a sharp cut-off
in activity, with saccharides dp14 and larger strongly acti-
vating FGF-1, the dp12 fraction activating very weakly
and smaller fractions being inactive (see Supplementary
material). As these size-defined fractions are complex mix-
tures, it is possible that some individual dp12 saccharides
are positive regulators of FGF-1 activity (as observed for
the dp10 fraction in the activation of FGF-2). Neverthe-
less, the activity profile is quite distinct from that for
FGF-2 signalling through FGFR1c. As for FGFR3c sig-
nalling, the basis for this size-dependent difference
remains to be determined. 
To demonstrate that the decasaccharide fractions contain
molecules with different structures, we analysed the disac-
charide compositions of selected fractions with different
activities (see Supplementary material). Each had a dis-
tinct composition, indicating differences in the primary
structure of the constituent saccharides. The profiles of
activation did not relate to general changes in charge
density and the level of sulphation (elution times corre-
lated broadly with charge density and increased levels of
sulphation), indicating that the HS saccharides contain
specific structural motifs responsible for their activities.
Indeed, variation in the levels of different structural
groups, particularly 2-O-sulphates and 6-O-sulphates, was
evident from the compositional analysis of the saccharides,
consistent with previous evidence that these modifications
are critical for regulation of FGF-2 signalling mediated by
FGFR1c [6,12,15]. Our results extend these observations
to the FGFR2c and FGFR3c isoforms, and show for the
first time that specific HS saccharide sequences are
designed for selective regulatory interactions with the
FGFR components of the FGF signalling pathway.
Recently, the primary structure of one of the decasac-
charides (the inhibitor designated X′) was established,
using a new technique for direct sequencing of HS sac-
charides ([16]; see Supplementary material). Previous
work indicated that the position of a 6-O-sulphate group
on glucosamine residues is critical for activation of
FGF-2 [15]. As 6-O-sulphate groups are not required for
FGF-2 binding [4,5], this implies that they play a role in
interactions with another protein, with the FGFR being
a probable candidate [15]. Interestingly, the sequence of
X′ indicates positioning of 6-O-sulphates on the two non-
reducing end disaccharide units, suggesting that the
location of 6-O-sulphates will be either central or reduc-
ing terminal in activating saccharides. It has been
reported that binding of HS and heparin chains to
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Figure 3
Possible mechanism of action of HS
saccharides on FGFR signalling. (a) HS
regulates FGF signalling by orchestrating the
formation of ternary signalling complexes of
FGFs with FGFRs. Through direct interactions
with both FGF ligands and FGFRs, HS can
regulate receptor dimerisation, trans-
phosphorylation of the intracellular tyrosine
kinase domains (TK) and triggering of
downstream signalling events. We propose
that specific HS decasaccharide motifs impart
specificity and altered binding affinity to these
interactions, and thus selectively enhance (or,
in some cases, inhibit) signalling by particular
ligand–receptor combinations.
Decasaccharides are probably on the
borderline of the minimal size required for
these interactions [9], and this may enhance
the differential activities we observed. For
simplicity, only the second and third
immunoglobulin (Ig)-like loops of the FGFR
(II and III) are shown. This model is based on
the recent co-crystal structure of FGF-2 with
FGFR1, which revealed a complex composed
of a symmetric dimer of two FGF–FGFR
complexes, with a putative heparin-binding
‘canyon’ between the interacting FGFR
domains [9]. This structure was crystallised in
the absence of heparin or HS saccharides,
however, and other possible configurations of
the FGF–FGFR complex have been proposed
on the basis of molecular modelling studies
[18]. (b) Top view of the complex to
emphasise the multiple interactions of the HS
decasaccharide motif with both the FGFRs
(through domain II) and FGF ligands.
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FGFR1 might involve an antithrombin-binding motif
containing a 3-O-sulphate group [17]. We found no evi-
dence to support this view, however, as none of the
bioactive decasaccharides we tested (both activators and
inhibitors of FGFR1 and FGFR2 signalling) showed any
ability to accelerate antithrombin III inhibition of
factor Xa (see Supplementary material).
A major goal of future studies will be the further purifica-
tion and sequencing of sets of individual decasaccharides
with similar abilities to regulate FGF-2 signalling medi-
ated by FGFR1c and FGFR2c. It will also be important
to determine the activities of individual saccharides from
the mixed-peak fractions. The approach we have
described can also be extended to larger HS saccharides
(for example, those required for activation of signalling by
FGF-1 or FGFR3c) and to a wider array of other FGF
ligand and receptor isoforms. These studies will permit
multiple structural comparisons to be made and allow
consensus saccharide motifs for particular activities to be
defined. In addition, we will be able to exploit, for the
first time, fully defined HS molecules in mechanistic
studies on the FGF–FGFR system.
The effects of the HS decasaccharides that we observed
are probably exerted through direct interactions with both
FGFs and FGFRs, a view supported by recent crystallo-
graphic data on an FGF-2–FGFR1 complex [9] and molec-
ular modelling studies [18] indicating that the HS-binding
regions of the two proteins are closely positioned in a
dimerised ligand–receptor complex. We propose that the
mechanism involves the participation of HS saccharide
motifs in the ligand–receptor complex in a way that
enhances receptor dimerisation, imparts specificity and
probably also increases binding affinity. One possible
model for these interactions is shown in Figure 3. The sig-
nalling outcome would depend on the balance of different
regulatory saccharide motifs expressed on the HS chains;
the precise spatial displays of their structural groups would
permit distinct interactions with the HS-binding domains
of the FGFs and FGFRs. In addition, the receptor speci-
ficity we have demonstrated presumably relates to differ-
ential interactions between the saccharides and divergent
sequences in the HS-binding region of the different FGFR
isoforms [9]. Cells can dynamically alter their expression of
specific HS sequences, for example, during development
[10]. This might provide a new mechanism by which cells
fine-tune their spatial and temporal responses to HS-
binding extracellular factors, and also restrict signalling by
particular ligand–receptor combinations. 
Supplementary material
Supplementary material including additional background and method-
ological detail, a figure showing differential activation of FGF signalling
by size-defined HS saccharides, and a table showing disaccharide
composition of selected decasaccharide fractions is available at
http://current-biology.com/supmat/supmatin.htm.
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Supplementary background
Recent genetic, biochemical and cell biological studies
have highlighted important functional roles for HS in
many cellular events including cell division, modulation
of signalling molecules, axon navigation, kidney develop-
ment and neurite outgrowth [S1–S6]. Some of these
studies have provided evidence that structural modifica-
tions within HS chains are crucial for these functional
roles [S3–S5]. The molecular basis for the activities of
HS is its ability to interact with and regulate the activi-
ties of many proteins, particularly growth factors. The
best studied example is the FGF family of growth
factors, where signalling through tyrosine kinase FGFRs
is known to be dependent on HS. The molecular deter-
minants for the interaction of FGF-2 with HS are now
well established, and there is growing evidence that
other members of the FGF family recognise different
structural motifs in HS [S7,S8]. This suggests the poten-
tial for differential binding and regulation of ligands by
HS. In addition, there is evidence that FGFRs also inter-
act with both heparin [S9] (a highly sulphated structural
analogue of HS) and with HS ([S10]; A. Powell and
J.E.T., unpublished observations); although the speci-
ficities of the latter interactions are not yet known, they
may also be regulatory. The mechanism by which HS
saccharides modulate FGF signalling remains to be fully
elucidated, but much evidence indicates that it involves
facilitation of ligand-induced receptor dimerisation. 
Supplementary materials and methods
Saccharide preparation and analysis
Size-fractionated HS saccharides were prepared by heparitinase treat-
ment of porcine mucosal HS (gift from Organon, Oss, Netherlands)
and Bio-Gel P-10 size exclusion chromatography as described previ-
ously [S11,S12]. These saccharide pools represent complex sulphated
sequences enriched in N-sulphated glucosamine, iduronate residues
and O-sulphate groups, which are resistant to heparitinase cleavage
[S11–S14]. SAX-HPLC of HS saccharides was performed on Propac
PA1 columns (4 × 250 mm; Dionex). Samples were eluted with a linear
gradient of sodium chloride (0–1.0 M over 90 min) [S15] and 0.2 ml
fractions corresponding to selected peaks were pooled, desalted on
Sephadex G-25 HiTrap columns (Pharmacia) and weighed before
bioassay analysis. SAX-HPLC separation of the decasaccharides pro-
duced a highly complex profile of different saccharide peaks (Figure 1).
The tightly clustered groups of peaks were pooled for simplicity for the
initial activity screen described here. At least some of the partially
resolved peaks represent an equilibrium of α and β anomers of the
same primary structure; resolution of these peaks is decreased by
running the columns at higher temperatures (data not shown). Others
represent different structures (probably sulphation isomers) with slight
variations in the disposition of their sulphate groups and
glucuronate/iduronate moieties. We are currently applying enhanced
separation protocols for these saccharides so that their individual activ-
ities can be tested. 
Assays for FGF-stimulated mitogenesis 
Activation of FGF signalling was measured in bioassays using a lym-
phoblastoid cell line (BaF3 cells), which lacks both endogenous HS
and FGFRs and normally requires addition of IL-3 for survival and
growth. Stable transfectants which express specific FGFR isoforms
[S16] can be used to screen the abilities of HS saccharides to regu-
late signalling, as in the absence of IL-3 the cells will grow in response
to appropriate FGFs only in the presence of activating HS or heparin
Supplementary material
Figure S1
Differential activation of FGF signalling by
size-defined HS saccharides. FGF-2
activation of (a) FGFR1c and (b) FGFR3c.
(c) FGF-1 activation of FGFR1c. Activation
of FGF-2 signalling was measured in
bioassays using HS-deficient BaF3 cells
expressing different FGFR isoforms as
described in the Supplementary materials
and methods. Responses to 1 nM FGF-2 or
FGF-1 were assessed in the presence of the
size-defined decasaccharide fractions shown
(300 nM; equivalent to 1 µg/ml for the dp10
fraction), relative to a positive control of
heparin (1 µg/ml). Assays were performed in
triplicate and expressed as a percentage
(mean ± SD) of the heparin control.
Saccharides ≤ dp6 displayed no activity in
these assays (data not shown).
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saccharides [S12,S16]. We examined signalling by BaF3 cells
expressing the immunoglobulin-like loop IIIc splice variant of the FGFR
isoforms 1, 2 and 3 (FGFR1c, FGFR2c and FGFR3c, respectively).
Note that the FGFR3c cells contain a chimaera of the extracellular
domain of FGFR3c and the transmembrane and intracellular domain of
FGFR1 [S16]. A colorimetric assay using the tetrazolium salt MTT
[S17] was used to assess the mitogenic responses of the BaF3 cells
expressing different FGFR isoforms to 1 nM FGF-2 and FGF-1
(18 ng/ml; R & D Systems) for 72 h. Porcine mucosal heparin (Sigma;
1 µg/ml) was used as a positive control. Assays were performed in
triplicate and expressed as a percentage (mean ± SD) of the heparin
control. Data from representative experiments are shown in the
figures. The response of the BaF3 cells to IL-3 was typically 110, 174
and 140% of the response to FGF-2 plus heparin control for FGFR1c,
FGFR2c and FGFR3c, respectively. Typical A570 values in the MTT
assay were: IL-3 control (0.550, 0.370, 0.441); background level con-
trols with no added FGF-2 or FGF-2 alone (0.114, 0.099, 0.093); and
FGF-2 plus heparin control (0.502, 0.212, 0.312) for cells expressing
FGFR1c, FGFR2c and FGFR3c, respectively. Responses to heparin
or HS saccharides alone are identical to the background controls, in
both transfected and non-transfected cells, demonstrating that the
saccharides must exert their actions through the transfected FGFRs.
Although our assay readout is long term and the events downstream
from the receptor not yet well defined, the unequivocal FGFR isoform
specificities in otherwise identical cell backgrounds can best be inter-
preted as involving a common step that is strongly dependent on
FGF–FGFR interactions. Previous work has shown that results from
BaF3 mitogenic assays and binding of FGFs to soluble FGFRs are in
good agreement, indicating that the cell assays accurately reflect
effects on these interactions [S18]. The readout from BaF cell assays
also agree with data from other cell types made HS dependent by
chlorate treatment [S19].
Measurement of anticoagulant activity of HS decasaccharides
The ability of selected HS decasaccharides (those described in the Table
S1) to accelerate antithrombin III inhibition of factor Xa was measured
using a commercial assay (Accucolor heparin kit, Sigma, catalogue
number CRS 106). Activity in this assay requires the presence of
antithrombin-III-binding sites containing a 3-O-sulphate group. None of
these decasaccharides displayed any detectable activity at concentra-
tions in the range 0.001–1 µg/ml, despite the parental HS having appre-
ciable activity (approximately 70 U/mg, compared with a porcine
intestinal mucosal heparin standard at 174 U/mg).
Structure of decasaccharide X′
The sequence of the inhibitory decasaccharide designated X′ was pre-
viously determined by integral glycan sequencing to be
∆HexA–GlcNS(6S)–IdoA(2S)–GlcNS(6S)–IdoA(2S)–GlcNS–IdoA(2
S)–GlcNS–IdoA–GlcNS [S15].
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Figure S2
HS saccharides act as positive and negative regulators of FGFR
signalling. (a,b) Ability of different concentrations of selected
decasaccharide fractions to activate signalling by 1 nM FGF-2,
mediated by (a) FGFR1c (heparin and fraction V) and (b) FGFR2c
(heparin and fraction D) in BaF3 cells. (c,d) Ability of different
concentrations of selected decasaccharides to inhibit signalling by
1 nM FGF-2, mediated by (c) FGFR1c (fraction X′) and FGFR2c
(fractions V and X′) in BaF3 cells, in the presence of a sub-maximal
dose of an activating regulator (heparin, 100 ng/ml). Assays were
performed in triplicate and expressed as a percentage (mean ± SD) of
the heparin control without added inhibitor. 
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